Skip to main content
Equibles
GANX logo

GANX · Gain Therapeutics, Inc.

Track GANX — free

Use GANX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.79 +0.02 (+1.14%) At close · Sep 2
Rebalance outlook locked
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Our projected cash outflows for the upcoming periods raise substantial doubt about our ability to continue as a going concern for at least 12 months from the issuance of the financial statements included elsewhere in this Quarterly Report. We will need to raise additional capital to fund continued operations beyond the second quarter of 2027.”
View the 10-Q filed Aug 11, 2026
Market Cap
$77.90M
Shares
43.64M

Gain Therapeutics, Inc. Earnings Call Transcripts

Quarterly earnings calls for Gain Therapeutics, Inc. (GANX), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Key facts CIK 1819411 CUSIP 36269B105 13F (30d) 42 filings 42 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)